Epidyolex
What Epidyolex is used for
Epidyolex is indicated for use as adjunctive therapy of seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome (DS), in conjunction with clobazam, for patients 2 years of age and older.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Epidyolex
- Active substance
- cannabidiol
- Disease area
- Lennox Gastaut Syndrome; Epilepsies, Myoclonic
- Medicine group
- Antiepileptics
- ATC code
- N03AX
- Marketing authorisation holder
- Jazz Pharmaceuticals Ireland Limited
- Authorised in the EU since
- 2019
Official information
In the USA
Same active substance: Epidiolex
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Epidyolex used for?
Epidyolex is indicated for use as adjunctive therapy of seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome (DS), in conjunction with clobazam, for patients 2 years of age and older.
What is the active substance in Epidyolex?
Epidyolex contains cannabidiol.
Who makes Epidyolex?
The EU marketing authorisation holder is Jazz Pharmaceuticals Ireland Limited.
Is Epidyolex an orphan medicine?
Yes. Epidyolex is designated an orphan medicine in the EU, for a rare disease (Lennox Gastaut Syndrome; Epilepsies, Myoclonic).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU